About alglucosidase alfa
Enzyme replacement therapy
Used for
- Long-term enzyme replacement for Pompe disease (acid alpha-glucosidase deficiency).
Usual adult dose
20 mg/kg by intravenous infusion every two weeks.
Usual dose in children
20 mg/kg by intravenous infusion every two weeks, including infants and children.
Common side effects
- Allergic or infusion-related reactions, including rash, fever, chills, or breathing difficulty.
- Headache, nausea, vomiting, or diarrhea.
- Low oxygen levels or breathing problems.
- Severe allergic reaction, including anaphylaxis.
Important warnings
- Infusion reactions can be severe or life-threatening; monitoring and emergency treatment must be available.
- Risk of severe reactions may be higher with heart or lung problems.
- Antibodies can develop and may affect treatment response or increase reaction risk.
- Use caution with kidney problems, which may increase risk from infusion-related medicines.
Pregnancy
Human pregnancy information is limited; use when treatment benefits outweigh potential risks.
Breastfeeding
It is unknown whether alglucosidase alfa enters breast milk; weigh treatment benefits against potential risks.
Interactions
- No established clinically important drug interactions are known.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.